Biotech Values

[DewDiligence]

GILD—More readable form of the SVR4 and partial SVR12 data from GILD’s phase-2 trial of Sofosbuvir + Ledipasvir (GS-5885) ± ribavirin in GT1 treatment-naïve and PI-experienced patients to be presented at AASLD:


Treatment-naïve; 8 weeks w/o ribavirin
SVR4=100% (20/20)
SVR12=95% (19/20)

Treatment-naïve; 8 weeks WITH ribavirin
SVR4=100% (21/21)
SVR12=100% (21/21)

Treatment-naïve; 12 weeks w/o ribavirin
SVR4=100% (19/19)
SVR12=TBD

PI-experienced; 12 Weeks w/o ribavirin
SVR4=95% (18/19)
SVR12=TBD

PI-experienced; 12 Weeks WITH ribavirin
SVR4=95% (20/21)
SVR12=TBD

Note: The 60 treatment-naïve patients were 53 GT1a (88%) and 7 GT1b (12%); the 40 PI-experienced patents were 34 GT1a (85%) and 6 GT1b (15%). 22 of the 40 PI-experienced patients (55%) had cirrhosis.